T cell-specific STAT3 deficiency abrogates lupus nephritis.

Area of Science:

• Immunology
• Molecular Biology
• Nephrology

Background:

• Signal transducer and activator of transcription 3 (STAT3) is crucial for T-cell responses to cytokines and chemokines.
• Elevated STAT3 activation is observed in T cells of patients with systemic lupus erythematosus (SLE).
• STAT3 mediates T-cell migration and T:B cell interactions, contributing to SLE pathogenesis.

Purpose of the Study:

• To investigate the role of STAT3 in T-cell pathophysiology within lupus nephritis.
• To evaluate STAT3 as a potential therapeutic target for lupus nephritis.

Main Methods:

• Utilized a CD4-driven CRE-Flox model to specifically silence STAT3 expression in T cells.
• Assessed disease development, including lymphadenopathy, splenomegaly, and glomerulonephritis, in STAT3-deficient lupus-prone mice.
• Employed a nephrotoxic serum model to evaluate the impact of T cell-specific STAT3 silencing on nephritis.

Main Results:

• Lupus-prone mice lacking STAT3 in T cells did not develop key autoimmune symptoms like lymphadenopathy, splenomegaly, or glomerulonephritis.
• Production of anti-dsDNA antibodies was significantly reduced in mice with silenced T-cell STAT3.
• T cell-specific STAT3 silencing ameliorated kidney damage in the nephrotoxic serum model of nephritis.

Conclusions:

• T cell-specific STAT3 silencing effectively hinders the development of autoimmune nephritis in mouse models.
• STAT3 inhibition in T cells impairs their ability to support autoantibody production by B cells and reduces tissue infiltration.
• Targeting STAT3 in T cells presents a promising therapeutic strategy for SLE, particularly lupus nephritis.